Research programme: adenosine receptor antagonists - CV Therapeutics
Latest Information Update: 14 May 2008
At a glance
- Originator CV Therapeutics
- Class Xanthines
- Mechanism of Action Adenosine A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 10 Apr 2008 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 13 Jul 2006 Preclinical trials in Asthma in USA (unspecified route)